Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer: a Single-arm, Ahead, Open-label Study
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Pyrotinib (Primary) ; Carboplatin; Docetaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 08 Aug 2019 Planned End Date changed from 30 Nov 2020 to 31 Jul 2021.
- 08 Aug 2019 Planned primary completion date changed from 30 Nov 2019 to 31 Jul 2020.
- 08 Aug 2019 Status changed from not yet recruiting to recruiting.